We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.13 | -1.23% | 90.56 | 90.45 | 91.40 | 91.74 | 90.45 | 91.24 | 1,638,797 | 16:40:00 |
From May 2022 to May 2024
9:38 ET -- GSK PLC and Sanofi SA are among the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. A U.S. judge dismissed a series of lawsuits, numbering in the tens of thousands, around the Zantac heartburn treatment that both GSK and Sanofi had marketed. The judge in a multidistrict ruling concluded there was no scientific evidence to support the claim Zantac's active ingredient was carcinogenic. The decision could be appealed. U.S.-traded shares of GSK and Sanofi opened roughly 0.9% and 1.8% lower, respectively. Dow Jones & Co. owns Factiva. (robb.stewart@wsj.com)
(END) Dow Jones Newswires
December 07, 2022 09:53 ET (14:53 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
